(CLDX) Celldex Therapeutics - Ratings and Ratios
Antibody, Monoclonal, Bispecific, Inflammation, Kit
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 55.4% |
| Value at Risk 5%th | 82.8% |
| Relative Tail Risk | -9.12% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.39 |
| Alpha | -3.43 |
| CAGR/Max DD | -0.11 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.451 |
| Beta | 1.077 |
| Beta Downside | 0.794 |
| Drawdowns 3y | |
|---|---|
| Max DD | 70.84% |
| Mean DD | 36.70% |
| Median DD | 36.49% |
Description: CLDX Celldex Therapeutics November 12, 2025
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is a U.S.-based biopharma focused on antibody therapeutics for severe inflammatory, allergic, and autoimmune conditions, with its headquarters in Hampton, New Jersey.
The company’s lead programs are Barzolvolimab (CDX-0159), a KIT-receptor monoclonal antibody targeting chronic urticaria, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis, and CDX-622, a bispecific antibody that simultaneously neutralizes thymic stromal lymphopoietin (TSLP) and depletes mast cells by starving them of stem cell factor.
As of the most recent 10-Q (Q2 2024), Celldex reported $115 million in cash and marketable securities, giving it runway through at least 2026 without additional financing-a key KPI for early-stage biotech cash burn management.
The chronic urticaria market is projected to exceed $4 billion by 2028, while the broader biologics segment for inflammatory skin diseases is growing at a CAGR of ~12%, providing a sizable addressable market for Celldex’s pipeline.
Given the high unmet need and the company’s differentiated dual-target approach, analysts should monitor upcoming Phase 2 readouts and the potential impact of FDA guidance on bispecific antibody pathways.
For a deeper, data-driven assessment of CLDX’s valuation and risk profile, you may find the ValueRay analytics platform useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-224.5m TTM) > 0 and > 6% of Revenue (6% = 156.0k TTM) |
| FCFTA -0.28 (>2.0%) and ΔFCFTA -8.76pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 21.5k% (prev 7485 %; Δ 14.0kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.28 (>3.0%) and CFO -179.5m > Net Income -224.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 13.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (66.4m) change vs 12m ago 0.19% (target <= -2.0% for YES) |
| Gross Margin -2352 % (prev 68.76%; Δ -2421 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.35% (prev 1.21%; Δ -0.86pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -9.93 (EBITDA TTM -246.3m / Interest Expense TTM -25.1m) >= 6 (WARN >= 3) |
Altman Z'' -41.60
| (A) 0.86 = (Total Current Assets 604.3m - Total Current Liabilities 46.5m) / Total Assets 648.4m |
| (B) -2.67 = Retained Earnings (Balance) -1.73b / Total Assets 648.4m |
| warn (B) unusual magnitude: -2.67 — check mapping/units |
| (C) -0.34 = EBIT TTM -249.7m / Avg Total Assets 735.8m |
| (D) -34.52 = Book Value of Equity -1.73b / Total Liabilities 50.1m |
| Total Rating: -41.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 40.35
| 1. Piotroski 0.0pt |
| 2. FCF Yield -15.91% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda 0.14 |
| 7. RoE -33.22% |
| 8. Rev. Trend 22.47% |
| 9. EPS Trend -76.47% |
What is the price of CLDX shares?
Over the past week, the price has changed by +8.99%, over one month by +24.10%, over three months by +28.77% and over the past year by +13.01%.
Is CLDX a buy, sell or hold?
- Strong Buy: 10
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CLDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.1 | 80.4% |
| Analysts Target Price | 53.1 | 80.4% |
| ValueRay Target Price | 29.2 | -0.8% |
CLDX Fundamental Data Overview November 25, 2025
P/S = 662.705
P/B = 2.8785
Beta = 1.135
Revenue TTM = 2.60m USD
EBIT TTM = -249.7m USD
EBITDA TTM = -246.3m USD
Long Term Debt = 2.62m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.55m USD (from shortTermDebt, last quarter)
Debt = 2.62m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -33.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.14b USD (1.72b + Debt 2.62m - CCE 583.2m)
Interest Coverage Ratio = -9.93 (Ebit TTM -249.7m / Interest Expense TTM -25.1m)
FCF Yield = -15.91% (FCF TTM -181.7m / Enterprise Value 1.14b)
FCF Margin = -6987 % (FCF TTM -181.7m / Revenue TTM 2.60m)
Net Margin = -8636 % (Net Income TTM -224.5m / Revenue TTM 2.60m)
Gross Margin = -2352 % ((Revenue TTM 2.60m - Cost of Revenue TTM 63.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev 100.0%)
Tobins Q-Ratio = 1.76 (Enterprise Value 1.14b / Total Assets 648.4m)
Interest Expense / Debt = 118.7% (Interest Expense 3.11m / Debt 2.62m)
Taxrate = 100.0% (out of range, set to none) (-157.9m / -157.9m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 13.01 (Total Current Assets 604.3m / Total Current Liabilities 46.5m)
Debt / Equity = 0.00 (Debt 2.62m / totalStockholderEquity, last quarter 598.4m)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -33.4m / EBITDA -246.3m)
Debt / FCF = 0.18 (negative FCF - burning cash) (Net Debt -33.4m / FCF TTM -181.7m)
Total Stockholder Equity = 675.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.63% (Net Income -224.5m / Total Assets 648.4m)
RoE = -33.22% (Net Income TTM -224.5m / Total Stockholder Equity 675.9m)
RoCE = -36.79% (EBIT -249.7m / Capital Employed (Equity 675.9m + L.T.Debt 2.62m))
RoIC = -1331 % (out of range, set to none) (EBIT -249.7m / (Assets 648.4m - Curr.Liab 46.5m - Cash 583.2m))
WACC = 9.96% (E(1.72b)/V(1.72b) * Re(9.98%) + (debt cost/tax rate unavailable))
Discount Rate = 9.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.99%
Fair Price DCF = unknown (Cash Flow -181.7m)
EPS Correlation: -76.47 | EPS CAGR: -46.18% | SUE: -1.22 | # QB: 0
Revenue Correlation: 22.47 | Revenue CAGR: -37.05% | SUE: -0.73 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.05 | Chg30d=-0.025 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-4.41 | Chg30d=-0.092 | Revisions Net=-3 | Growth EPS=-23.3% | Growth Revenue=+27.5%
Additional Sources for CLDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle